Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection?

ABSTRACT: Traumatic brain injury (TBI) constitutes a major health problem worldwide and is a leading cause of death and disability in individuals, contributing to devastating socioeconomic consequences. Despite numerous promising pharmacological strategies reported as neuroprotective in preclinical studies, the translation to clinical trials always failed, albeit the great diversity of therapeutic targets evaluated. In this review, first, we described epidemiologic features, causes, and primary and secondary injuries of TBI. Second, we outlined the current literature on animal models of TBI, and we described their goals, their advantages and disadvantages according to the species used, the type of injury induced, and their clinical relevance. Third, we defined the concept of neuroprotection and disc

SUBMITTER: Lerouet D 

PROVIDER: S-EPMC9290810 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature